The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.a

Left or biventricular dysfunction/failure

Publications

Jerkins JH, Suciu A, Mazimba S, Calvo A

Bortezomib-induced Severe Congestive Heart Failure.

Cardiology research 2010 Dec;1;20-23 — 2010 Dec — 20-23

Aota Y, Gotoh A, Hanyu N, Honma T, Morisaki M, Yokoyama T, Kitagawa N, Komatsu N

[Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma].

[Rinsho ketsueki] The Japanese journal of clinical hematology 2015 Jan;56;44-7 — 2015 Jan — 44-7

Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R

Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.

Acta haematologica 2012;128;244-7 — 2012 — 244-7

Voortman J, Giaccone G

Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.

BMC cancer 2006 May 11;6;129 — 2006 May 11 — 129